Citigroup Inc Allovir, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Allovir, Inc. stock. As of the latest transaction made, Citigroup Inc holds 990 shares of ALVR stock, worth $544. This represents 0.0% of its overall portfolio holdings.

Number of Shares

990

Previous 7,645 87.05%

Holding current value

$544

Previous $5,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.7 - $0.82 $4,658 - $5,457	-6,655 Reduced 87.05%	990 $0
Q2 2024 Aug 12, 2024	SELL	$0.72 - $0.82 $2,017 - $2,297	-2,802 Reduced 26.82%	7,645 $5,000
Q1 2024 May 10, 2024	BUY	$0.64 - $0.78 $1,905 - $2,322	2,978 Added 39.87%	10,447 $7,000
Q4 2023 Feb 09, 2024	BUY	$0.68 - $2.39 $4,040 - $14,201	5,942 Added 389.13%	7,469 $5,000
Q3 2023 Nov 09, 2023	SELL	$2.15 - $3.64 $30,037 - $50,854	-13,971 Reduced 90.15%	1,527 $3,000
Q2 2023 Aug 10, 2023	BUY	$3.17 - $5.82 $41,032 - $75,334	12,944 Added 506.81%	15,498 $52,000
Q1 2023 May 11, 2023	SELL	$3.94 - $7.05 $153 - $274	-39 Reduced 1.5%	2,554 $10,000
Q4 2022 Feb 09, 2023	BUY	$4.7 - $9.98 $75 - $159	16 Added 0.62%	2,593 $13,000
Q3 2022 Nov 10, 2022	SELL	$4.13 - $8.79 $15,830 - $33,692	-3,833 Reduced 59.8%	2,577 $20,000
Q2 2022 Aug 10, 2022	BUY	$3.26 - $7.06 $1,271 - $2,753	390 Added 6.48%	6,410 $25,000
Q1 2022 May 12, 2022	SELL	$6.75 - $13.52 $346,801 - $694,630	-51,378 Reduced 89.51%	6,020 $41,000
Q4 2021 Feb 10, 2022	BUY	$12.94 - $25.99 $327,394 - $657,572	25,301 Added 78.83%	57,398 $743,000
Q3 2021 Nov 10, 2021	BUY	$16.97 - $25.06 $544,686 - $804,350	32,097 New	32,097 $804,000

Others Institutions Holding ALVR

# of Institutions

Shares Held

44.6M

Call Options Held

14.9K

Put Options Held

200

View Full List

About Allovir, Inc.

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

More about ALVR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account